DDInter1610 DDInter262
Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.[L15128,L15133]
Rivastigmine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cabozantinib
Rivastigmine {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cabozantinib
Rivastigmine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Aprepitant
Aprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Rivastigmine {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Aprepitant
Aprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Rivastigmine {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Dabrafenib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Rivastigmine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Rivastigmine {u} (Compound) causes {v} (Side Effect) Coordination abnormal
Coordination abnormal {u} (Side Effect) is caused by {v} (Compound) Epirubicin
Epirubicin {u} may lead to a major life threatening interaction when taken with {v} Cabozantinib
Rivastigmine {u} (Compound) causes {v} (Side Effect) Pyuria
Pyuria {u} (Side Effect) is caused by {v} (Compound) Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Cabozantinib
Rivastigmine {u} (Compound) causes {v} (Side Effect) Skin exfoliation
Skin exfoliation {u} (Side Effect) is caused by {v} (Compound) Ponatinib
Ponatinib {u} may lead to a major life threatening interaction when taken with {v} Cabozantinib
Rivastigmine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rifabutin
Rifabutin {u} may lead to a major life threatening interaction when taken with {v} Cabozantinib
Rivastigmine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Rivastigmine (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Rivastigmine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Aprepitant (Compound) and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Rivastigmine (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Aprepitant (Compound) and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Rivastigmine (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Dabrafenib (Compound) and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Rivastigmine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound) and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Rivastigmine (Compound) causes Coordination abnormal (Side Effect) and Coordination abnormal (Side Effect) is caused by Epirubicin (Compound) and Epirubicin may lead to a major life threatening interaction when taken with Cabozantinib
Rivastigmine (Compound) causes Pyuria (Side Effect) and Pyuria (Side Effect) is caused by Flurbiprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib and Flurbiprofen may lead to a major life threatening interaction when taken with Cabozantinib
Rivastigmine (Compound) causes Skin exfoliation (Side Effect) and Skin exfoliation (Side Effect) is caused by Ponatinib (Compound) and Ponatinib may lead to a major life threatening interaction when taken with Cabozantinib
Rivastigmine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rifabutin (Compound) and Rifabutin may lead to a major life threatening interaction when taken with Cabozantinib